vs

Side-by-side financial comparison of Coterra (CTRA) and ResMed (RMD). Click either name above to swap in a different company.

Coterra is the larger business by last-quarter revenue ($1.8B vs $1.4B, roughly 1.3× ResMed). ResMed runs the higher net margin — 27.6% vs 20.6%, a 7.0% gap on every dollar of revenue. On growth, Coterra posted the faster year-over-year revenue change (23.8% vs 11.0%). Over the past eight quarters, Coterra's revenue compounded faster (11.8% CAGR vs 7.9%).

Coterra Energy Inc. is an American energy company engaged in hydrocarbon exploration based in Houston, Texas. The company has operations in the Permian Basin, Marcellus Shale, and the Anadarko Basin.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

CTRA vs RMD — Head-to-Head

Bigger by revenue
CTRA
CTRA
1.3× larger
CTRA
$1.8B
$1.4B
RMD
Growing faster (revenue YoY)
CTRA
CTRA
+12.8% gap
CTRA
23.8%
11.0%
RMD
Higher net margin
RMD
RMD
7.0% more per $
RMD
27.6%
20.6%
CTRA
Faster 2-yr revenue CAGR
CTRA
CTRA
Annualised
CTRA
11.8%
7.9%
RMD

Income Statement — Q4 FY2025 vs Q4 FY2026

Metric
CTRA
CTRA
RMD
RMD
Revenue
$1.8B
$1.4B
Net Profit
$368.0M
$392.6M
Gross Margin
61.8%
Operating Margin
31.9%
34.6%
Net Margin
20.6%
27.6%
Revenue YoY
23.8%
11.0%
Net Profit YoY
23.9%
13.9%
EPS (diluted)
$0.47
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRA
CTRA
RMD
RMD
Q2 26
$1.4B
Q4 25
$1.8B
$1.4B
Q3 25
$1.8B
$1.3B
Q2 25
$1.7B
$1.3B
Q1 25
$2.0B
$1.3B
Q4 24
$1.4B
$1.3B
Q3 24
$1.3B
$1.2B
Q2 24
$1.3B
$1.2B
Net Profit
CTRA
CTRA
RMD
RMD
Q2 26
$392.6M
Q4 25
$368.0M
$392.6M
Q3 25
$322.0M
$348.5M
Q2 25
$511.0M
$379.7M
Q1 25
$516.0M
$365.0M
Q4 24
$297.0M
$344.6M
Q3 24
$252.0M
$311.4M
Q2 24
$220.0M
$292.2M
Gross Margin
CTRA
CTRA
RMD
RMD
Q2 26
61.8%
Q4 25
61.8%
Q3 25
61.5%
Q2 25
60.8%
Q1 25
59.3%
Q4 24
58.6%
Q3 24
58.6%
Q2 24
58.5%
Operating Margin
CTRA
CTRA
RMD
RMD
Q2 26
34.6%
Q4 25
31.9%
34.6%
Q3 25
26.8%
33.4%
Q2 25
40.9%
33.7%
Q1 25
34.8%
33.0%
Q4 24
22.5%
32.5%
Q3 24
25.3%
31.6%
Q2 24
23.0%
31.2%
Net Margin
CTRA
CTRA
RMD
RMD
Q2 26
27.6%
Q4 25
20.6%
27.6%
Q3 25
18.3%
26.1%
Q2 25
29.5%
28.2%
Q1 25
25.6%
28.3%
Q4 24
20.5%
26.9%
Q3 24
19.5%
25.4%
Q2 24
17.1%
23.9%
EPS (diluted)
CTRA
CTRA
RMD
RMD
Q2 26
$2.68
Q4 25
$0.47
$2.68
Q3 25
$0.42
$2.37
Q2 25
$0.67
$2.58
Q1 25
$0.68
$2.48
Q4 24
$0.40
$2.34
Q3 24
$0.34
$2.11
Q2 24
$0.29
$1.97

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRA
CTRA
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$114.0M
$1.4B
Total DebtLower is stronger
$3.8B
$663.8M
Stockholders' EquityBook value
$14.8B
$6.3B
Total Assets
$24.2B
$8.5B
Debt / EquityLower = less leverage
0.26×
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRA
CTRA
RMD
RMD
Q2 26
$1.4B
Q4 25
$114.0M
$1.4B
Q3 25
$98.0M
$1.4B
Q2 25
$192.0M
$1.2B
Q1 25
$186.0M
$932.7M
Q4 24
$2.0B
$521.9M
Q3 24
$843.0M
$426.4M
Q2 24
$1.3B
$238.4M
Total Debt
CTRA
CTRA
RMD
RMD
Q2 26
$663.8M
Q4 25
$3.8B
$403.9M
Q3 25
$3.9B
$408.7M
Q2 25
$4.2B
$658.4M
Q1 25
$4.3B
$663.1M
Q4 24
$3.5B
$662.9M
Q3 24
$2.1B
$667.6M
Q2 24
$2.6B
$697.3M
Stockholders' Equity
CTRA
CTRA
RMD
RMD
Q2 26
$6.3B
Q4 25
$14.8B
$6.3B
Q3 25
$14.7B
$6.1B
Q2 25
$14.6B
$6.0B
Q1 25
$14.2B
$5.5B
Q4 24
$13.1B
$5.3B
Q3 24
$13.0B
$5.2B
Q2 24
$13.0B
$4.9B
Total Assets
CTRA
CTRA
RMD
RMD
Q2 26
$8.5B
Q4 25
$24.2B
$8.5B
Q3 25
$24.0B
$8.3B
Q2 25
$24.0B
$8.2B
Q1 25
$24.0B
$7.6B
Q4 24
$21.6B
$7.1B
Q3 24
$20.1B
$7.2B
Q2 24
$20.8B
$6.9B
Debt / Equity
CTRA
CTRA
RMD
RMD
Q2 26
0.11×
Q4 25
0.26×
0.06×
Q3 25
0.27×
0.07×
Q2 25
0.29×
0.11×
Q1 25
0.30×
0.12×
Q4 24
0.27×
0.13×
Q3 24
0.16×
0.13×
Q2 24
0.20×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRA
CTRA
RMD
RMD
Operating Cash FlowLast quarter
$970.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.64×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRA
CTRA
RMD
RMD
Q2 26
Q4 25
$970.0M
$339.7M
Q3 25
$971.0M
$457.3M
Q2 25
$936.0M
$538.8M
Q1 25
$1.1B
$578.7M
Q4 24
$626.0M
$308.6M
Q3 24
$755.0M
$325.5M
Q2 24
$558.0M
$440.1M
Free Cash Flow
CTRA
CTRA
RMD
RMD
Q2 26
Q4 25
$311.2M
Q3 25
$414.4M
Q2 25
$508.2M
Q1 25
$557.9M
Q4 24
$288.0M
Q3 24
$307.7M
Q2 24
$415.2M
FCF Margin
CTRA
CTRA
RMD
RMD
Q2 26
Q4 25
21.9%
Q3 25
31.0%
Q2 25
37.7%
Q1 25
43.2%
Q4 24
22.5%
Q3 24
25.1%
Q2 24
33.9%
Capex Intensity
CTRA
CTRA
RMD
RMD
Q2 26
Q4 25
2.0%
Q3 25
3.2%
Q2 25
2.3%
Q1 25
1.6%
Q4 24
1.6%
Q3 24
1.5%
Q2 24
2.0%
Cash Conversion
CTRA
CTRA
RMD
RMD
Q2 26
Q4 25
2.64×
0.87×
Q3 25
3.02×
1.31×
Q2 25
1.83×
1.42×
Q1 25
2.22×
1.59×
Q4 24
2.11×
0.90×
Q3 24
3.00×
1.05×
Q2 24
2.54×
1.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTRA
CTRA

Oil And Condensate$941.0M53%
Natural Gas Production$615.0M34%
Natural Gas Liquids Reserves$206.0M12%
Other Revenues$28.0M2%

RMD
RMD

Segment breakdown not available.

Related Comparisons